Eli Lilly Wins Multiple Domain Disputes Over Mounjaro Trademark Amid Financial Surge
Feb/07/2025
Eli Lilly and Company secured victories in multiple WIPO domain disputes to protect its MOUNJARO trademark, reflecting the pharmaceutical giant’s stance on safeguarding its intellectual property amid soaring product sales. The company prevailed in cases over <mounjarobrasil.shop> and <mounjaro-fr.shop>. MOUNJARO, an FDA-approved injectable for type 2 diabetes, generated $11.54 billion globally in 2024, contributing significantly to Eli Lilly’s 45% year-over-year revenue growth in Q4. The WIPO panel found the domains confusingly similar to the company’s trademarks, reinforcing Eli Lilly’s commitment to protecting its brand integrity. These legal victories coincide with the company’s financial boom, as net income doubled to $4.41 billion in Q4 2024, fueled by MOUNJARO’s success alongside other key products like Zepbound and Verzenio. Eli Lilly projects 2025 revenue between $58 billion and $61 billion, with continued growth in its diabetes and obesity treatment portfolio.
